期刊文献+

进展期胃癌分子靶向治疗的研究进展 被引量:4

Research progress of molecular targeted therapy for advanced gastric cancer
下载PDF
导出
摘要 胃癌是目前全球癌症死亡的第二大原因,早期诊断困难,传统的手术和放化疗治疗进展期胃癌的有效率低。随着对肿瘤发病机制研究的不断深入,分子靶向治疗成为肿瘤治疗的发展趋势。这些靶向治疗策略主要包括:HER2单克隆抗体、表皮生长因子受体抑制剂、血管生成抑制剂、mTOR抑制剂、细胞周期蛋白依赖性激酶(CDKs)、基质金属蛋白酶(MMPS)抑制剂/c-Met抑制剂/IGF-1R抑制剂/HSP90抑制剂等。本文就进展期胃癌近年来分子靶向治疗的研究结果及相关进展做一综述。 Gastric cancer (GC) is currently the second leading cause of cancer death worldwide, and early di-agnosis is difficult and the efficacy of surgery, radiotherapy and chemotherapy for advanced GC is poor. With the deep-ening of study on pathogenesis of tumor, molecular targeted therapy has become a trend for cancer therapy. These ther-apeutic strategies include targeting HER2 monoclonal antibody, EGFR signal transduction pathway, anti-angiogenesis, PI3k/Akt/mTOR pathway inhibitors, multityrosine kinase inhibitors, cyclin dependent kinase (CDK) inhibitors, matrix metalloproteinase inhibitors, c-Met inhibitors, IGF-1R inhibitors and HSP90 inhibitors. This article focuses on summa-rize the most recent the development of targeted therapy for advanced gastric cancer.
出处 《海南医学》 CAS 2014年第9期1321-1324,共4页 Hainan Medical Journal
关键词 胃癌 分子靶向治疗 Stomach neoplasms Molecular targeted therapy
  • 相关文献

参考文献24

  • 1Garon EB, Cao D, Alexandris E, et al. A randomized, double-blind,phase III study of Docetaxel and Ramucirumab versus Docetaxeland placebo in the treatment of stage IV non-small-cell lung cancerafter disease progression after 1 previous platinum-based therapy(REVEL): treatment rationale and study design [J]. Clin Lung Can-cer, 2012, 13(6): 505-509.
  • 2Lieto E, Ferraraccio F, Orditura M, et al. Expression of vascular en-dothelial growth factor (VEGF) and epidermal growth factor recep-tor (EGFR) is an independent prognostic indicator of worse out-come in gastric cancer patients [J]. Ann Suig Oncol, 2008, 15(1):69-79.
  • 3Kim MA, Lee HS, Lee HE, et al. EGFR in gastric carcinomas: prog-nostic significance of protein overexpression and high gene copynumber [J]. Histopathology, 2008,52(6): 738-746.
  • 4Arteaga C. Targeting HER1/EGFR: a molecular approach to cancertherapy [J]. Semin Oncol, 2003,30(3 Suppl 7): 3-14.
  • 5Iqbal S, Goldman B,Fenoglio-Preiser CM, et ai. Southwest Oncolo-gy Group study S0413: a phase II trial of lapatinib (GW572016) asfirst-line therapy in patients with advanced or metastatic gastric can-cer [J]. Ann Oncol, 2011,22(12): 2610-2615.
  • 6Hecht JR, Bang Y, Sobrero A, et al. A phase III study of Capeox+/-lapatinibin HER2 in in HER2 postive locally-advanced/metastaticupper gastrointestinal adenocarcinoma: interim safety results [J].EJC Suppl, 2009,7(2): 385.
  • 7Yonemura Y,Ninomiya I,Yamaguchi A, et al. Evaluation of immu-noreactivity for erbB-2 protein as a marker of poor short term prog-nosis in gastric cancer [J]. Cancer Res, 1991, 51(3): 1034-1038.
  • 8Kim JW, Im SA, Kim M, et al. The prognostic significance ofHER2 positivity for advanced gastric cancer patients undergoingfirst-line modified FOLFOX-6 regimen [J]. Anticancer Res, 2012,32(4): 1547-1553.
  • 9Wainberg ZA, Anghel A, Desai AJ, et al. Lapatinib, a dual EGFRand HER2 kinase inhibitor, selectively inhibits HER2~amplified hu-man gastric cancer cells and is synergistic with trastuzumab in vitroand in vivo [J]. Clin Cancer Res, 2010,16(5): 1509-1519.
  • 10Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in com-bination with chemotherapy versus chemotherapy alone for treat-ment of HER2-positive advanced gastric or gastro-oesophagealjunction cancer (ToGA): a phase 3, open-label, randomised con-trolled trial [J]. Lancet, 2010, 376(9742): 687-697.

二级参考文献14

  • 1Shia J,Klimstra DS,Li AR,et al.Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma:an immunohistochemical and chromogenic in situ hybridization study[J].Mod Pathol,2005,18:1350-1356.
  • 2Kim MA,Lee HS,Lee HE,et al.EGFR in gastric carcinomas:prognostic significance of protein overexpression and high gene copy number[J].Histopathology,2008,52:738-746.
  • 3Yamada A,Saito N,Kameoka S,et al.Clinical significance of epidermal growth factor(EGF) expression in gastric cancer[J].Hepatogastroenterology,2007,54:1049-1052.
  • 4Celikel C,Eren F,Gulluoglu B,et al.Relation of neuroendocrine cells to transforming growth factor-alpha and epidermal growth factor receptor expression in gastric adenocarcinomas:prognostic implications[J].Pathol Oncol Res,2007,13:215-226.
  • 5Pino MS,Shrader M,Baker CH,et al.Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib(iressa) in human pancreatic cancer cell lines[J].Cancer Res,2006,66:3802-3812.
  • 6Karapetis CS,Khambata-Ford S,Jonker DJ,et al.K-ras mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med,2008,359:1757-1765.
  • 7Lee KH,Lee JS,Suh C,et al.Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer.An analysis of 140 cases[J].Cancer,1995,75:2794-2801.
  • 8Han S,Park SR,Lee K,et al.Phase Ⅱ study and biomarker analysis of cetuximab in combination with oxaliplatin,5-fluorouracil,leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer[J].J Clin Oncol,2008,26:a4549.
  • 9Lordick F,Lorenzen S,Hegewisch-Becker S,et al.Cetuximab plus weekly oxaliplatin/5FU/FA(FUFOX) in 1st line metastatic gastric cancer.Final results from a multicenter phase Ⅱ study of the AIO upper GI study group[J].J Clin Oncol,2007,25:4526a.
  • 10Pinto C,Di Fabio F,Siena S,et al.Phase Ⅱ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma(FOLCETUX study)[J].Ann Oncol,2007,18:510-517.

共引文献11

同被引文献57

  • 1王绯,杨永平.HSP90抑制剂靶向治疗癌症研究进展[J].解放军医学杂志,2006,31(3):274-275. 被引量:6
  • 2Whitesell L, Lindquist SL. Hsp90 and the chaperoning of cancer [ J]. Nature Reviews Cancer, 2005,5 ( 10 ) : 761 - 772.
  • 3Chen MH, Chiang KC, Cheng CT, et al. Antitumor activity of the combination of an Hsp90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma [ J]. Oncotarget, 2014,5 ( 9 ) : 2372 - 2389.
  • 4Trepel J, Mollapour M, Giaccone G, et al. Targeting the dy- namic l-Isp90 complex in cancer[ J]. Nature Reviews Cane- er,2010,10(8 ) :537 - 549.
  • 5Camidge DR, Doebele RC. Treating ALK -positive lung cancer- early successes and future challenges [ J ]. Nat Rev Clin Onco1,2012,9 ( 5 ) :268 - 277.
  • 6Smith CC, Wang Q, Chin CS. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leuke- mia [ J ]. Nature ,2012,485 ( 7397 ) :260 - 263.
  • 7Taipale M ,Jarosz DF,Lindquist S. Hsp90 at the hub of pro- tein homeostasis:emerging mechanistic insights [ J ]. Nat Rev Mol Cell Biol,2010,11 (7):515 -528.
  • 8Solit DB, Chiosis G. Development and application of Hsp90 inhibitors [ J]. Drug Discovery Today, 2008,13 ( 1 ) :38 - 43.
  • 9Cowen LE, Singh SD, Ktihler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strate- gy for fungal infectious disease [ J]. Proc Natl Acad Sci USA ,2009,106 (8) :2818 - 2823.
  • 10Lee KH,Lee JH, Han SW, et al. Antitumor activity of NVP - AUY922, a novel heat shock protein 90 inhibitor, in hu- man gastric cancer cells is mediated through proteasomal degradation of client proteins [ J]. Cancer Science, 2011, 102(7) :1388 - 1395.

引证文献4

二级引证文献62

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部